The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Practice Guidelines for the Treatment of Coccidioidomycosis
Open accessAbstract
Management of patients diagnosed with coccidioidomycosis involves defining the extent of infection and assessing host factors that predispose to disease severity. Patients with relatively localized acute pulmonary infections and no risk factors for complications often require only periodic reassessment to demonstrate resolution of their self-limited process. On the other hand, patients with extensive spread of infection or at high risk of complications because of immunosuppression or other preexisting factors require a variety of treatment strategies that may include antifungal therapy, surgical debridement, or both. Amphotericin B is often selected for treatment of patients with respiratory failure due to Coccidioides immitis or rapidly progressive coccidioidal infections. With other more chronic manifestations of coccidioidomycosis, treatment with fluconazole, itraconazole, or ketoconazole is common. Duration of therapy often ranges from many months to years, and, for some patients, chronic suppressive therapy is needed to prevent relapses. Coccidioidomycosis results from inhaling the spores (arthroconidia) of Coccidioides immitis. Most infections in the United States occur within the major regions of endemicity in southern Arizona, central California, southern New Mexico, and west Texas. Travelers who visit these regions of endemicity and immunosuppressed patients in whom latent infections reactivate can require medical management in other parts of the country [1]. Of the estimated 100,000 infections per year, one-half to two-thirds are subclinical, and most patients with these infections are protected from second primary infections. The most common clinical presentation in diagnosed cases of coccidioidomycosis is acute or subacute pneumonic illness. Approximately 5%–10% of infections result in residual pulmonary sequelae, usually nodules or peripheral thin-walled cavities. An even smaller proportion of all infections, perhaps 0.5%–1.0%, result in illnesses related to chronic pulmonary or extrapulmonary infection. Although virtually any site in the body may be involved, extrapulmonary dissemination most frequently involves the skin, the skeletal system, and the meninges [2–4]. Objective. The objective of this practice guideline is to provide recommendations about which patients with coccidioidomycosis are likely to benefit from treatment and for which therapies are most appropriate for various forms of infection. Treatment options. Coccidioidomycosis encompasses a spectrum of illnesses ranging from primary uncomplicated respiratory tract infection that resolves spontaneously to progressive pulmonary or disseminated infection. For this reason, management strategies vary widely from patient to patient. Although disease will resolve in most patients who present with early infections without specific antifungal therapy, management should routinely include repeated patient encounters for 1–2 years, either to document resolution or to identify, as early as possible, evidence of pulmonary or extrapulmonary complications. Patients who develop progressive pulmonary disease or disseminated disease warrant antifungal therapy, which is typically prolonged—potentially lifelong—especially for patients with overt immunocompromised conditions. Exact management guidelines for these clinical forms will vary according to disease type and, to an extent, must be individualized. For example, the role of surgical debridement, which in some cases is a critical component of therapy, is not addressed in this practice guideline. However, all patients with progressive or disseminated disease will require some combination of periodic physical examinations, laboratory studies, and radiological studies to guide management decisions. Specific antifungals (and their usual dosages) for treatment of coccidioidomycosis include amphotericin B (0.5–0.7 mg/kg/d iv), ketoconazole (400 mg/d po), fluconazole (400–800 mg/d po or iv), and itraconazole (200 mg b.i.d. po). If itraconazole is used, measurement of serum concentrations of itraconazole after 2 weeks may determine if absorption is satisfactory. In general, the more rapidly progressive a coccidioidal infection is, the more likely amphotericin B will be selected by most authorities for initial therapy. Conversely, subacute or chronic presentations are more likely to be treated initially with an azole. Outcomes. Desired outcomes of treatment are resolution of signs and symptoms of infection, reduction of serum concentrations of antibodies to C. immitis, and return of function of involved organs. It would also be desirable to prevent relapse of illness upon discontinuation of therapy, although current therapy is often unable to achieve this goal. Evidence. Before the availability of antifungal therapy, the natural history of initial pulmonary infections revealed that these infections resolved in at least 95% of patients. Randomized, prospective clinical trials of antifungals have not been co
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serology of coccidioidomycosis
Pappagianis, D., & Zimmer, B. L. (1990) · Clinical Microbiology Reviews · doi:10.1128/cmr.3.3.247 · Cited by 382
Stevens, D. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504203321607 · Cited by 338
Self-citationIs It Ever Safe To Stop Azole Therapy for Coccidioides immitis Meningitis?
Dewsnup, D. H., Galgiani, J. N., Graybill, J. R., Diaz, M., Rendon, A., Cloud, G. A., & Stevens, D. A. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-3-199602010-00004 · Cited by 207
Self-citationFluconazole Therapy for Coccidioidal Meningitis
Galgiani, J. N., Catanzaro, A., Cloud, G. A., Higgs, J., Friedman, B. A., Larsen, R. A., Graybill, J. R., & and NIAID-Mycoses Study Group. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-1-199307010-00005 · Cited by 206
Self-citationDrutz, D. J., & Catanzaro, A. (1978) · PubMed · doi:10.1164/arrd.1978.117.3.559 · Cited by 176
Self-citationItraconazole treatment of coccidioidomycosis
Graybill, J. R., Stevens, D. A., Galgiani, J. N., Dismukes, W. E., & Cloud, G. A. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90339-f · Cited by 164
Self-citationItraconazole Therapy for Chronic Coccidioidal Meningitis
TUCKER, R. M., Denning, D. W., Dupont, B., & Stevens, D. A. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-2-108 · Cited by 148
Self-citationFluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis
Catanzaro, A., Galgiani, J. N., Levine, B. E., Sharkey, P. K., Fierer, J., Stevens, D. A., Chapman, S. W., & Cloud, G. A. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80371-4 · Cited by 137
Self-citationA Pan-American 5-Year Study of Fluconazole Therapy for Deep Mycoses in the Immunocompetent Host
Díaz, M. C., Negroni, R., Montero-Gei, F., Castro, L. G. M., Sampaio, S. A. P., Borelli, D., Restrepo, Á., Franco, L., Bran, J. L., Arathoon, E., et al. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.supplement_1.s68 · Cited by 136
Self-citationCoccidioidal Meningitis: AN ANALYSIS OF THIRTY-ONE CASES AND REVIEW OF THE LITERATURE
Bouza, E., Dreyer, J. S., HEWITT, W. L., & Meyer, R. D. (1981) · Medicine · doi:10.1097/00005792-198105000-00001 · Cited by 131
Al-Attraqchi, A. A. F., Hassan, J. S., & Hadi, A. S. (2018) · International Journal of Research in Pharmaceutical Sciences · doi:10.26452/ijrps.v9ispl1.1306 · Cited by 104
Treatment of Mycoses with Itraconazole
TUCKER, R. M., Williams, P. L., Arathoon, E., et al. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb40443.x · Cited by 93
Self-citationKetoconazole therapy of progressive coccidioidomycosis
Galgiani, J. N., Stevens, D. A., Graybill, J. R., Dismukes, W. E., & Cloud, G. A. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90143-x · Cited by 92
Self-citation(1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-5-719_5 · Cited by 84
Practice Guidelines for the Treatment of Fungal Infections
Sobel, J. D., & Mycoses Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/313746 · Cited by 77
Coccidioidal meningitis. The use of amphotericin B in treatment.
Einstein, H. E., Holeman, C. W., Sandidge, L. L., & HOLDEN, D. H. (1961) · PubMed · Cited by 73
Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis
Stevens, D. A., Stiller, R. L., Williams, P. L., et al. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90515-6 · Cited by 64
Self-citationAmphotericin B in the Treatment of Coccidioidomycosis
Drutz, D. J. (1983) · Drugs · doi:10.2165/00003495-198326040-00003 · Cited by 53
Itraconazole in the Treatment of Coccidioidomycosis
Díaz, M. C., Puente, R., de Hoyos, L. A., & Cruz, S. D. L. (1991) · CHEST Journal · doi:10.1378/chest.100.3.682 · Cited by 44
Fluconazole in the Treatment of Persistent Coccidioidomycosis
Catanzaro, A., Fierer, J., & Friedman, P. J. (1990) · CHEST Journal · doi:10.1378/chest.97.3.666 · Cited by 36
Self-citationTomecki, K. J. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90739-2 · Cited by 26
Cited by
Limper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Self-citationGalgiani, J. N., Ampel, N. M., Blair, J. E., Catanzaro, A., Johnson, R. H., Stevens, D. A., & Williams, P. L. (2005) · Clinical Infectious Diseases · doi:10.1086/496991 · Cited by 603
Self-citationSegal, B. H., Herbrecht, R., Stevens, D. A., Ostrosky‐Zeichner, L., Sobel, J., Viscoli, C., Walsh, T. J., Maertens, J., Patterson, T. F., Perfect, J. R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590566 · Cited by 468
Self-citationGalgiani, J. N., Catanzaro, A., Cloud, G. A., Johnson, R. H., Williams, P. L., Mirels, L. F., Nassar, F., Lutz, J. E., Stevens, D. A., Sharkey, P. K., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-9-200011070-00009 · Cited by 294
Self-citationCrum, N. F., Lederman, E. R., Stafford, C. M., Parrish, J. S., & Wallace, M. R. (2004) · Medicine · doi:10.1097/01.md.0000126762.91040.fd · Cited by 265
Metadata
- Authors
- Galgiani, J. N., Ampel, N. M., Catanzaro, A., Johnson, R. H., Stevens, D. A., & Williams, P. L.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 30
- Issue
- 4
- Pages
- 658-661
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2164174337
- Cited by
- 275
- References
- 21
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.